JP2006525811A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525811A5
JP2006525811A5 JP2006514886A JP2006514886A JP2006525811A5 JP 2006525811 A5 JP2006525811 A5 JP 2006525811A5 JP 2006514886 A JP2006514886 A JP 2006514886A JP 2006514886 A JP2006514886 A JP 2006514886A JP 2006525811 A5 JP2006525811 A5 JP 2006525811A5
Authority
JP
Japan
Prior art keywords
sirna
sequence
nucleotides
nucleotide sequence
target gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525811A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/015439 external-priority patent/WO2005018534A2/en
Publication of JP2006525811A publication Critical patent/JP2006525811A/ja
Publication of JP2006525811A5 publication Critical patent/JP2006525811A5/ja
Pending legal-status Critical Current

Links

JP2006514886A 2003-05-16 2004-05-17 Rna干渉の方法と組成物 Pending JP2006525811A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47139203P 2003-05-16 2003-05-16
US51522303P 2003-10-27 2003-10-27
PCT/US2004/015439 WO2005018534A2 (en) 2003-05-16 2004-05-17 Methods and compositions for rna interference

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010202235A Division JP2011004763A (ja) 2003-05-16 2010-09-09 Rna干渉の方法と組成物

Publications (2)

Publication Number Publication Date
JP2006525811A JP2006525811A (ja) 2006-11-16
JP2006525811A5 true JP2006525811A5 (enExample) 2007-07-05

Family

ID=34221197

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006514886A Pending JP2006525811A (ja) 2003-05-16 2004-05-17 Rna干渉の方法と組成物
JP2010202235A Pending JP2011004763A (ja) 2003-05-16 2010-09-09 Rna干渉の方法と組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010202235A Pending JP2011004763A (ja) 2003-05-16 2010-09-09 Rna干渉の方法と組成物

Country Status (5)

Country Link
US (1) US8609830B2 (enExample)
EP (1) EP1628993A4 (enExample)
JP (2) JP2006525811A (enExample)
CA (1) CA2525619A1 (enExample)
WO (1) WO2005018534A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US8447526B2 (en) 2005-05-23 2013-05-21 Microsoft Corporation Methods and computer systems for analyzing high-throughput assays
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2008137862A2 (en) * 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Methods of using mir34 as a biomarker for tp53 functional status
IN2009KN04568A (enExample) 2007-06-01 2015-08-28 Univ Princeton
KR101840618B1 (ko) * 2008-12-04 2018-03-20 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
US20130131148A1 (en) * 2010-04-12 2013-05-23 Noam Shomron Micro-rna for cancer diagnosis, prognosis and therapy
DE102011009470A1 (de) * 2011-01-21 2012-08-09 Friedrich-Schiller-Universität Jena Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit
WO2012143427A1 (en) * 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
JP2022551204A (ja) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー Cd71結合フィブロネクチンiii型ドメイン
MX2023012128A (es) 2021-04-14 2024-01-11 Aro Biotherapeutics Company Dominios tipo iii de la fibronectina que se unen a cd71.
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
PT969102E (pt) 1991-09-24 2008-03-25 Keygene Nv Iniciadores, grupos e conjuntos de fragmentos de restrição usados na amplificação selectiva de fragmentos de restrição
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6165709A (en) 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6028189A (en) 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
WO1998041531A2 (en) 1997-03-20 1998-09-24 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6217002B1 (en) * 1998-01-13 2001-04-17 Terry C. Shafer Valve assembly having floating retainer rings
US5965352A (en) 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
US6324479B1 (en) 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6132969A (en) 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
US6950752B1 (en) 1998-10-27 2005-09-27 Rosetta Inpharmatics Llc Methods for removing artifact from biological profiles
US6801859B1 (en) 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
US6351712B1 (en) 1998-12-28 2002-02-26 Rosetta Inpharmatics, Inc. Statistical combining of cell expression profiles
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
US20020016216A1 (en) 1999-06-08 2002-02-07 Kenji Kobayashi Golf club
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
WO2002018464A2 (en) 2000-08-29 2002-03-07 Mallinckrodt Baker Inc. Functionalized polymeric media for separation of analytes
WO2002044399A2 (en) 2000-11-28 2002-06-06 Rosetta Inpharmatics, Inc. In vitro transcription method for rna amplification
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US20020182590A1 (en) * 2001-05-25 2002-12-05 Vanderbilt University Determining protein function in cell culture using RNA interference
CA2921821A1 (en) 2001-07-12 2003-01-23 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
US7418351B2 (en) 2002-01-31 2008-08-26 Rosetta Inpharmatics Llc Methods for analysis of measurement errors in measured signals
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
US7996155B2 (en) 2003-01-22 2011-08-09 Microsoft Corporation ANOVA method for data analysis
EP1692262B1 (en) 2003-10-27 2018-08-15 Merck Sharp & Dohme Corp. Method of designing sirnas for gene silencing

Similar Documents

Publication Publication Date Title
JP2006525811A5 (enExample)
Fernandes et al. Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs
Tan et al. Transcriptional inhibiton of Hoxd4 expression by miRNA-10a in human breast cancer cells
US11193171B2 (en) Diagnostic, prognostic and therapeutic uses of long noncoding RNAS for heart disease and regenerative medicine
Wang et al. Role of microRNAs in cardiac hypertrophy and heart failure
Danowski et al. Decreased expression of miR-133a but not of miR-1 is associated with signs of heart failure in patients undergoing coronary bypass surgery
JP2011200238A5 (enExample)
Pacholewska et al. Novel equine tissue miRNAs and breed-related miRNA expressed in serum
JP2012135301A5 (enExample)
Hong et al. Differential regulation of microRNA transcriptome in chicken lines resistant and susceptible to necrotic enteritis disease
CN1890370A (zh) RNAi潜能的预测方法
JP2010530239A5 (enExample)
JP2011004763A (ja) Rna干渉の方法と組成物
Zhao et al. MiR-7-5p enhances cerebral ischemia–reperfusion injury by degrading sirt1 mRNA
Cheng et al. LncRNA MALAT1 regulates proliferation and apoptosis of vascular smooth muscle cells by targeting miRNA-124-3p/PPARα axis.
Miao et al. Critical roles of microRNAs in the pathogenesis of systemic sclerosis: New advances, challenges and potential directions
Latronico et al. microRNAs in hypertrophy and heart failure
Henshall Manipulating microRNAs in murine models: targeting the multi-targeting in epilepsy
Abubakar et al. Non-coding RNA-mediated gene regulation in cardiovascular disorders: current insights and future directions
Oladejo et al. MicroRNAome: potential and veritable immunomolecular therapeutic and diagnostic baseline for lingering bovine endometritis
JP2022163074A (ja) 心肥大におけるマイクロRNA hsa-miR-665
WO2015085904A1 (zh) 禽流感病毒miRNA及其鉴定、检测和应用
CN108977443A (zh) 一种表达动脉粥样硬化炎症活动的环状rna及其应用
CN103981267A (zh) 一种microRNA在猪肌内脂肪检测中的应用
US9909127B2 (en) Inhibitor for inhibiting avian influenza virus and a pharmaceutical composition containing the same